These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease. Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120 [TBL] [Abstract][Full Text] [Related]
3. Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis. Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM BMC Neurosci; 2018 Jul; 19(1):46. PubMed ID: 30055565 [TBL] [Abstract][Full Text] [Related]
4. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Durairajan SS; Liu LF; Lu JH; Chen LL; Yuan Q; Chung SK; Huang L; Li XS; Huang JD; Li M Neurobiol Aging; 2012 Dec; 33(12):2903-19. PubMed ID: 22459600 [TBL] [Abstract][Full Text] [Related]
5. A third-generation mouse model of Alzheimer's disease shows early and increased cored plaque pathology composed of wild-type human amyloid β peptide. Sato K; Watamura N; Fujioka R; Mihira N; Sekiguchi M; Nagata K; Ohshima T; Saito T; Saido TC; Sasaguri H J Biol Chem; 2021 Sep; 297(3):101004. PubMed ID: 34329683 [TBL] [Abstract][Full Text] [Related]
6. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R J Neurosci; 2012 Sep; 32(38):13125-36. PubMed ID: 22993429 [TBL] [Abstract][Full Text] [Related]
7. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Dutescu RM; Li QX; Crowston J; Masters CL; Baird PN; Culvenor JG Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1213-21. PubMed ID: 19271231 [TBL] [Abstract][Full Text] [Related]
8. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. Melnikova T; Fromholt S; Kim H; Lee D; Xu G; Price A; Moore BD; Golde TE; Felsenstein KM; Savonenko A; Borchelt DR J Neurosci; 2013 Feb; 33(9):3765-79. PubMed ID: 23447589 [TBL] [Abstract][Full Text] [Related]
9. An isogenic panel of Watamura N; Sato K; Shiihashi G; Iwasaki A; Kamano N; Takahashi M; Sekiguchi M; Mihira N; Fujioka R; Nagata K; Hashimoto S; Saito T; Ohshima T; Saido TC; Sasaguri H Sci Adv; 2022 Jun; 8(23):eabm6155. PubMed ID: 35675411 [TBL] [Abstract][Full Text] [Related]
10. Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Rönnbäck A; Sagelius H; Bergstedt KD; Näslund J; Westermark GT; Winblad B; Graff C Neurobiol Aging; 2012 Apr; 33(4):831.e11-9. PubMed ID: 21880397 [TBL] [Abstract][Full Text] [Related]
11. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021 [TBL] [Abstract][Full Text] [Related]
12. Reduction in open field activity in the absence of memory deficits in the App Whyte LS; Hemsley KM; Lau AA; Hassiotis S; Saito T; Saido TC; Hopwood JJ; Sargeant TJ Behav Brain Res; 2018 Jan; 336():177-181. PubMed ID: 28887197 [TBL] [Abstract][Full Text] [Related]
13. Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease. Armstrong P; Güngör H; Anongjanya P; Tweedy C; Parkin E; Johnston J; Carr IM; Dawson N; Clapcote SJ Neuropsychopharmacology; 2024 Sep; 49(10):1559-1568. PubMed ID: 38521860 [TBL] [Abstract][Full Text] [Related]
14. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence. Kindy MS; Yu J; Zhu H; El-Amouri SS; Hook V; Hook GR J Alzheimers Dis; 2012; 29(4):827-40. PubMed ID: 22337825 [TBL] [Abstract][Full Text] [Related]
15. Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice. Hoshino T; Murao N; Namba T; Takehara M; Adachi H; Katsuno M; Sobue G; Matsushima T; Suzuki T; Mizushima T J Neurosci; 2011 Apr; 31(14):5225-34. PubMed ID: 21471357 [TBL] [Abstract][Full Text] [Related]
16. Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease. Oulès B; Del Prete D; Greco B; Zhang X; Lauritzen I; Sevalle J; Moreno S; Paterlini-Bréchot P; Trebak M; Checler F; Benfenati F; Chami M J Neurosci; 2012 Aug; 32(34):11820-34. PubMed ID: 22915123 [TBL] [Abstract][Full Text] [Related]
17. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868 [TBL] [Abstract][Full Text] [Related]
18. Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse. Plucińska K; Crouch B; Yeap JM; Stoppelkamp S; Riedel G; Platt B J Alzheimers Dis; 2018; 65(1):165-180. PubMed ID: 30040726 [TBL] [Abstract][Full Text] [Related]
19. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. Kimura R; Devi L; Ohno M J Neurochem; 2010 Apr; 113(1):248-61. PubMed ID: 20089133 [TBL] [Abstract][Full Text] [Related]
20. Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression. Saito T; Matsuba Y; Yamazaki N; Hashimoto S; Saido TC J Neurosci; 2016 Sep; 36(38):9933-6. PubMed ID: 27656030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]